CD248 and neoplasm: Among these patients, 78 (62.90%) showed CD248 expression in >50% of the tumor-associated vasculature (score 2), 38 (30.65%) showed CD248 expression in ≤50% of the tumor-associated vasculature (score 1), respectively, while 8 (6.45%) did not show detectable CD248 expression (score 0) (Table 2).